These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Preparation and immunogenicity of vaccine Ac NFU1 (S-) MRC towards the prevention of herpes genitalis. Skinner GR; Woodman CB; Hartley CE; Buchan A; Fuller A; Durham J; Synnott M; Clay JC; Melling J; Wiblin C; Wilkins J Br J Vener Dis; 1982 Dec; 58(6):381-6. PubMed ID: 6293640 [TBL] [Abstract][Full Text] [Related]
5. Early experience with "antigenoid" vaccine Ac NFU1(S-) MRC towards prevention or modification of herpes genitalis. Skinner GR; Woodman C; Hartley C; Buchan A; Fuller A; Wiblin C; Wilkins G; Melling J Dev Biol Stand; 1982; 52():333-44. PubMed ID: 6299842 [TBL] [Abstract][Full Text] [Related]
6. Efficacy of vaccination with Skinner vaccine towards the prevention of herpes simplex virus induced cervical carcinoma in an experimental mouse model. Chen MH; Zhou Z; Hartley CE; Cowan M; Skinner GR Vaccine; 1986 Dec; 4(4):249-52. PubMed ID: 3026107 [TBL] [Abstract][Full Text] [Related]
13. Clinical efficacy of a herpes simplex subunit vaccine. Cappel R; Sprecher S; De Cuyper F; De Braekeleer J J Med Virol; 1985 Jun; 16(2):137-45. PubMed ID: 2989419 [TBL] [Abstract][Full Text] [Related]
14. Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection: two randomized controlled trials. Chiron HSV Vaccine Study Group. Corey L; Langenberg AG; Ashley R; Sekulovich RE; Izu AE; Douglas JM; Handsfield HH; Warren T; Marr L; Tyring S; DiCarlo R; Adimora AA; Leone P; Dekker CL; Burke RL; Leong WP; Straus SE JAMA; 1999 Jul; 282(4):331-40. PubMed ID: 10432030 [TBL] [Abstract][Full Text] [Related]
15. Efficacy of vaccine Ac NFU1 (S-) MRC 5 given after an initial clinical episode in the prevention of herpes genitalis. Woodman CB; Buchan A; Fuller A; Hartley C; Skinner GR; Stocker D; Sugrue D; Clay JC; Wilkins G; Wiblin C Br J Vener Dis; 1983 Oct; 59(5):311-3. PubMed ID: 6311322 [TBL] [Abstract][Full Text] [Related]
16. Vaccines against genital herpes: progress and limitations. Morrison LA Drugs; 2002; 62(8):1119-29. PubMed ID: 12010075 [TBL] [Abstract][Full Text] [Related]
17. Control of herpes simplex virus infections of the genital tract by vaccination. Buchan A; Skinner GR; Fuller A; Hartley C; Hallworth J; Stocker D; Melling J; Wiblin C Vaccine; 1985 Mar; 3(1):49-53. PubMed ID: 4002836 [TBL] [Abstract][Full Text] [Related]
18. Immunization against genital herpes with a vaccine virus that has defects in productive and latent infection. Da Costa XJ; Jones CA; Knipe DM Proc Natl Acad Sci U S A; 1999 Jun; 96(12):6994-8. PubMed ID: 10359827 [TBL] [Abstract][Full Text] [Related]
19. Hypothetical vaccination of the Dutch population with a herpes simplex virus vaccine: estimation of the profitability using a demographic projection model. Bos CA Vaccine; 1988 Aug; 6(4):309-14. PubMed ID: 2847437 [TBL] [Abstract][Full Text] [Related]
20. Herpes simplex virus genital infection of the female guinea pig as a model for the evaluation of an experimental vaccine. Thornton B; Baskerville A; Bailey NE; Melling JM; Hambleton P Vaccine; 1984 Jun; 2(2):141-8. PubMed ID: 6099646 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]